The FDA has approved Janssen's Xarelto to preventstroke in patients with an abnormal heart rhythm called atrial fibrillation -- with a strong "black box" warning.
A black box warning is the FDA's strongest warning.
Xarelto now joins Boehringer Ingelheim's Pradaxa as alternatives towarfarin (brand names include Coumadin and Jantoven) to preventstroke-causing blood clots in patients with atrial fibrillation not caused by a heart valve problem. Atrial fibrillation often puts a person at increased risk of blood clots and stroke.
Like Warfarin, Xarelto is a blood thinner -- an anti-clotting drug. These products can cause dangerous bleeding. But Xarelto can also increase the risk of stroke if people stop taking it without medical supervision. That's the main warning in the "black box" on the Xarelto label.